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Rat hepatocytes were incubated in monolayer cuhure, under serum-free conditions for 8 h. Rat growth 
hormone (up to 100 nM) increased the activity of phosphatidate phosphohydrolase by up to 47%. Insuhn 
(500 pM or 35 nM), cycloheximide or actinomycin D reversed this effect. The ability of growth hormone 
to modify the effects of insulin is discussed in relation to the control of the phosphohydrolase activity and 
glycerolipid synthesis. 
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The role of growth hormone in the control of 
hepatic lipid metabolism has received relatively lit- 
tle attention. Growth hormone can inhibit acetyl- 
CoA carboxylase through an increase in its 
phosphorylation state [I] and can stimulate the P- 
oxidation of saturated fatty acids [2]. Injection of 
growth hormone into rats led to an increase in 
hepatic phosphatidate phosphohydrolase activity 
after a period of 4 h f3]* but it was not clear 
whether this was a direct effect of tbe hormone 
itself. 
The activity of phosphatidate phospbohydrolase 
has been shown to be increased in the long term by 
glucagon and dexamethasone, these increases be- 
ing reversed by insulin [4,5] and to some extent by 
spermine (unpublished). The metabolic expression 
of the phosphohydrolase activity occurs when the 
cytosolic form of the enzyme translocates to the 
endoplasmic reticulum. This occurs when the 
supply of fatty acids to the liver increases f6,7J. It 
is thought that changes in the activity and 
subcell&u distribution of this enzyme are impor- 
tant in the control of hepatic triacylglycerol syn- 
thesis [7], 
It has been extensively reported that growth hor- 
mone has the ability to modify insulin sensitivity in 
a variety of tissues [8-l I]. Generally, growth hor- 
mone excess leads to a state of insulin resistance, 
whereas growth hormone deficiency leads to a 
state of increased insulin sensitivity. Although the 
exact mechanism of growth hormone action is not 
fully understood, modifications of the insulin 
receptor [11,12] or of cyclic AMP metabolism 
fZ 3- 15] have been implicated. Paradoxically 
however, growth hormone has also been shown to 
possess insulin-like activity [16,I7J. An increase in 
plasma growth hormone has been reported to lead 
to a transient insulin-like effect on glucose 
clearance (after 1-2 h) followed by insulin an- 
tagonistic effects (after 6 h) [16]. It has also been 
reported that a growth hormone fragment (amino 
acids 6- 13) stimulated glycogen synthesis whereas 
another fragment (ammo acids 177-191) led to a 
stimulation of glycogeno~ys~s f17]. This may be ex- 
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plained by variants of growth hormone having 
metabolic effects [ 181. 
The following experiments were performed to 
determine whether growth hormone can modify 
the activity of phosphatidate phosphohydrolase 
directly or by modifying the effects of insulin, or 
other hormones. To do this the enzyme was 
measured in a rat hepatocyte culture system under 
serum-free conditions. We have shown that growth 
hormone can directly increase phosphatidate 
phosphohydrolase activity and that this effect is 
antagonised by insulin. 
2. MATERIALS AND METHODS 
The sources of the rats and most of the materials 
have been described [4]. Rat growth hormone was 
kindly donated by the National Institute of Ar- 
thritis, Metabolism and Digestive Diseases, USA. 
The activity was 1.7 IU/mg, containing 
0.07 IU/mg of TSH activity. 
Hepatocytes were prepared and attached to 
Primaria tissue culture dishes in Leibowitz-L15 
medium containing 10% (v/v) newborn calf 
serum. They were maintained for the next 12-18 h 
in Leibowitz-L15 medium containing 0.2% (w/v) 
fatty acid-poor bovine serum albumin before 
beginning the experiments [4]. Phosphatidate 
phosphohydrolase [ 191 and lactate dehydrogenase 
activities [20] were measured in cell homogenates 
[4] as described. The total phosphohydrolase ac- 
tivity was expressed relative to that of lactate 
dehydrogenase to compensate for slight variations 
in cell number between different culture dishes. 
3. RESULTS AND DISCUSSION 
Incubation of hepatocytes for 8 h with rat 
growth hormone increased the activity of phos- 
phatidate phosphohydrolase by up to 47% in 10 in- 
dependent experiments. A significant increase was 
seen with a hormone concentration of 0.1 nM 
(table 1, column A). This increase was not ap- 
parent until after 4-6 h and seemed to reach a 
maximum after approx. 12 h (fig.1). The presence 
of the protein synthesis inhibitors, actinomycin D 
Table 1 
Effects of growth hormone, insulin, dexamethasone and inhibitors of protein synthesis on the activity of phosphatidate 
phosphohydrolase in cultured hepatocytes 
Growth hormone 
concentration 
(nM) (A) 
None 
Additions 
(B) (C) (D) (E) (F) 
Insulin Dexamethasone Dexamethasone Actinomycin Cycloheximide 
(500 pM or (100 nM) (1OOnM) + (1 @g/ml) (5 pg/ml) 
35 nM) insulin (35 nM 
or 500 PM) 
I 0 100 (10) 106 + 32 (8) 385 + 123 (9) 134 f 38 (6) 92 it- 22 (3) 102 + 30 (3) 
II 0.1 119 + 11 (7) 95 f 17 (3) 363 f 110 (4) 217 + 87 (5) 
I vs IIC 
II 1.0 121 + 14 (7) 102 * 7 (4) 431 + 99 (5) 193 + 51 (5) 
I vs IIIC 
IV 10 147 + 42 (10) 103 k 20 (6) 472 ZIZ 113 (6) 182 f 24 (5) 119 rL 39 (3) 82 +- 4 (3) 
I vs IV’ AIV vs BIVa 
v 100 144 t- 35 (6) 111 + 38 (4) 427 f 97 (4) 155 10 (2) f 
I vs VB AV vs BVb 
Cultured rat hepatocytes were incubated for 8 h with the indicated concentrations of hormones and inhibitors. The total 
phosphohydrolase activity is expressed relative to incubations in which no extra additions were made which was 0.332 f 
0.235 nmol diacylglycerol produced/min per unit lactate dehydrogenase activity. Results are given as means f SD 
(numbers of independent experiments). The significance of the effects of growth hormone and insulin were calculated 
by using a paired r-test and shown by a P < 0.05; b P < 0.02 and ’ P < 0.01 
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Fig.1. Effect of growth hormone on the activity of 
phosphatidate phosphohydrolase in cultured rat 
hepatocytes. The cells were incubated in the absence (0) 
or presence of 100 pM growth hormone (0) for the 
times indicated. The results show the mean f ranges of 
the relative phosphohydrolase activity for duplicate 
plates in one experiment. The activity at the beginning of 
the incubation period was taken as 100% and was 
0.35 mmol diacylglycerol produced/min per unit lactate 
dehydrogenase activity 
(1 pg/ml) or cycloheximide (5 pg/ml) abolished 
this increase without significantly affecting the 
phosphohydrolase activity in control incubations 
(table 1, columns E,F). This suggests that growth 
hormone, like dexamethasone and glucagon [5], 
may be acting by increasing the synthesis of the en- 
zyme. Insulin at either 500 pM or 35 nM was 
equally effective in abolishing the effects of growth 
hormone without affecting the phosphohydrolase 
activity when added alone. 
The incubation of hepatocytes with growth hor- 
mone and dexamethasone in combination pro- 
duced additive increases in the phosphohydrolase 
activity in 4 out of 6 independent experiments 
(table 1, column C). However, these effects were 
mostly masked by the variability of the dexa- 
methasone-mediated increase in the phospho- 
hydrolase activity when compared with the rela- 
tively small effects of growth hormone in these ex- 
periments. If cyclic AMP did accumulate within 
the cell on incubation with growth hormone, then 
additive or synergistic increases in the phospho- 
hydrolase would be expected, as was seen with in- 
cubations containing dexamethasone and cyclic 
AMP [4] or glucagon [5]. 
Growth hormone appeared to increase the ac- 
tivity of phosphatidate phosphohydrolase in in- 
cubations that contained dexamethasone and in- 
sulin (table 1, column D). This effect was however 
quite varied in magnitude and not statistically 
significant. The increases een were larger than the 
effects of growth hormone alone in some ex- 
periments and may occur because the growth hor- 
mone antagonises the effects of insulin. 
Growth hormone and glucocorticoids [ 11,121 
have both been reported to lead to a state of insulin 
resistance through a decrease in the affinity of in- 
sulin binding to its receptor or in receptor number 
[ll, 121. If this were the case then a preincubation 
of hepatocytes with growth hormone could 
enhance the possible anti-insulin-like effects thus 
decreasing the effects of insulin in antagonising the 
dexamethasone- or glucagon-mediated increases in 
the phosphohydrolase activity. 
The long-term regulation of phosphatidate 
phosphohydrolase activity is under complex hor- 
monal control. Dexamethasone, cyclic AMP 
analogues, glucagon [4,5] and growth hormone 
can increase its activity, probably by increasing its 
rate of synthesis. Insulin has the ability to an- 
tagonise these increases, although insulin sensitivi- 
ty may be decreased in the long term by growth 
hormone and glucocorticoids [l 1,121. It is not yet 
known whether growth hormone can acutely alter 
the activation of the phosphohydrolase through its 
translocation from the cytosolic to membrane- 
associated compartments in response to an in- 
creased fatty acid supply. Growth hormone may 
indirectly affect the translocation ‘in viva’ as it has 
been reported to stimulate lipolysis in adipose 
tissue leading to an increase in the circulating con- 
centration of fatty acids [21,22]. Growth hormone 
secretion, as well as that of glucagon and glucocor- 
ticoids, is increased in conditions, such as stress, 
starvation or hypoglycaemia [23]. 
The present results indicate that growth hor- 
mone could increase the capacity of the liver to 
synthesise glycerolipids in stress conditions by in- 
creasing the total reservoir of phosphatidate 
phosphohydrolase activity. Expression of this ac- 
tivity will probably rely mainly on the net ac- 
cumulation of fatty acids and their CoA esters in 
the liver [7]. 
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